October 2, 2019
Ono Pharmaceutical/Bristol Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) significantly extended overall survival (OS) in a PIII trial in esophageal cancer patients, the primary endpoint of the study, and reduced the risk of death by 23%, the companies said on September...read more